131 related articles for article (PubMed ID: 10405534)
1. [Cost-effectiveness analysis of cardiovascular disease prevention: a graded list as aid to the rational distribution of resources].
Lindholm L; Hallgren CG; Boman K; Markgren K; Weinehall L; Ogren JE
Lakartidningen; 1999 Jun; 96(23):2858-63, 2865-6. PubMed ID: 10405534
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease?
Lindholm L; Hallgren CG; Boman K; Markgren K; Weinehall L; Ogren JE
Health Policy; 1999 Sep; 48(3):155-70. PubMed ID: 11067036
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
4. The role of resource allocation models in selecting clinical preventive services.
Wang LY; Haddix AC; Teutsch SM; Caldwell B
Am J Manag Care; 1999 Apr; 5(4):445-54. PubMed ID: 10387384
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
Marshall T
Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of lipid-lowering treatment according to lipid level.
Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
[TBL] [Abstract][Full Text] [Related]
7. [Can we afford good cholesterol lowering therapy? Budgeting of statin costs versus medical needs in the county of Stockholm].
Wettermark B; Hjemdahl P
Lakartidningen; 2001 Nov; 98(48):5472-3, 5476-8, 5481-3. PubMed ID: 11769362
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
10. [Guidelines and costs].
Casparie AF; van Hout BA; Simoons ML
Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2075-7. PubMed ID: 9856218
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
[TBL] [Abstract][Full Text] [Related]
12. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
[TBL] [Abstract][Full Text] [Related]
13. Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings.
Mendis S; Lindholm LH; Anderson SG; Alwan A; Koju R; Onwubere BJ; Kayani AM; Abeysinghe N; Duneas A; Tabagari S; Fan W; Sarraf-Zadegan N; Nordet P; Whitworth J; Heagerty A
J Clin Epidemiol; 2011 Dec; 64(12):1451-62. PubMed ID: 21530172
[TBL] [Abstract][Full Text] [Related]
14. Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases.
Annemans L; Lamotte M; Clarys P; Van den Abeele E
Eur J Cardiovasc Prev Rehabil; 2007 Dec; 14(6):815-24. PubMed ID: 18043305
[TBL] [Abstract][Full Text] [Related]
15. Primary prevention of cardiovascular disease: cost-effectiveness comparison.
Franco OH; der Kinderen AJ; De Laet C; Peeters A; Bonneux L
Int J Technol Assess Health Care; 2007; 23(1):71-9. PubMed ID: 17234019
[TBL] [Abstract][Full Text] [Related]
16. [Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].
Keiding H; Hildebrandt P; Alemao E; Davies GM
Ugeskr Laeger; 2008 Jun; 170(26-32):2323-6. PubMed ID: 18570764
[TBL] [Abstract][Full Text] [Related]
17. A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease.
Liew D; Lim SS; Bertram M; McNeil JJ; Vos T
Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):515-22. PubMed ID: 16874139
[TBL] [Abstract][Full Text] [Related]
18. Strategic and cost effective role for preventive cardiology.
Dunn PJ; Ryan MJ; Hiebert M
J Cardiovasc Manag; 1998; 9(6):13-20. PubMed ID: 10350995
[No Abstract] [Full Text] [Related]
19. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level.
Gaziano TA; Steyn K; Cohen DJ; Weinstein MC; Opie LH
Circulation; 2005 Dec; 112(23):3569-76. PubMed ID: 16330698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
